Study to Analyze safety, effectiveness and compliance of erythropoietin therapy using WEPOX® Dispopen, A new delivery device, in the management of CKD Anemia
Phase 4
- Conditions
- Health Condition 1: D758- Other specified diseases of bloodand blood-forming organs
- Registration Number
- CTRI/2022/07/043917
- Lead Sponsor
- Wockhardt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients newly prescribed with WEPOX Dispopen 20000 IU for anemia due to chronic kidney disease (CKD)
Patient willing to comply with the protocol and written Informed Consent
Exclusion Criteria
Patients who do not meet requirement as per prescribing information of WEPOX Dispopen 20000 IU
Pregnant and lactating females
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method